Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.30
-0.92 (-0.38%)
AAPL  290.79
-10.75 (-3.57%)
AMD  468.86
-21.47 (-4.38%)
BAC  54.27
+0.63 (1.18%)
GOOG  362.19
+1.02 (0.28%)
META  586.58
+1.19 (0.20%)
MSFT  403.33
-8.41 (-2.04%)
NVDA  206.62
-2.02 (-0.97%)
ORCL  204.75
-7.07 (-3.34%)
TSLA  396.48
-12.47 (-3.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.